Literature DB >> 12583823

Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy.

Alexander M M Eggermont1, Timo L M ten Hagen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12583823     DOI： 10.1007/s11912-003-0091-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  7 in total

1.  TNF is here to stay--revisited.

Authors:  T L ten Hagen; A M Eggermont; F J Lejeune
Journal:  Trends Immunol       Date:  2001-03       Impact factor: 16.687

2.  Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver.

Authors:  H R Alexander; D L Bartlett; S K Libutti; D L Fraker; T Moser; S A Rosenberg
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

3.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

Authors:  D Lienard; P Ewalenko; J J Delmotte; N Renard; F J Lejeune
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

4.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.

Authors:  A M Eggermont; H Schraffordt Koops; J M Klausner; B B Kroon; P M Schlag; D Liénard; A N van Geel; H J Hoekstra; I Meller; O E Nieweg; C Kettelhack; G Ben-Ari; J C Pector; F J Lejeune
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

5.  Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.

Authors:  T L Ten Hagen; A H Van Der Veen; P T Nooijen; S T Van Tiel; A L Seynhaeve; A M Eggermont
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

6.  Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma.

Authors:  C Rüegg; A Yilmaz; G Bieler; J Bamat; P Chaubert; F J Lejeune
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

7.  Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.

Authors:  J H de Wilt; T L ten Hagen; G de Boeck; S T van Tiel; E A de Bruijn; A M Eggermont
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640
  7 in total
  5 in total

Review 1.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

2.  Melanoma and rheumatoid arthritis (brief report).

Authors:  Sarah Perkins; Martin Cohen; Elham Rahme; Sasha Bernatsky
Journal:  Clin Rheumatol       Date:  2012-01-13       Impact factor: 2.980

Review 3.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

4.  Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

Authors:  W G Dixon; K D Watson; M Lunt; L K Mercer; K L Hyrich; D P M Symmons
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-06       Impact factor: 4.794

5.  TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.

Authors:  Gary J Haderski; Bojidar M Kandar; Craig M Brackett; Ilia M Toshkov; Christopher P Johnson; Geraldine M Paszkiewicz; Venkatesh Natarajan; Anatoli S Gleiberman; Andrei V Gudkov; Lyudmila G Burdelya
Journal:  PLoS One       Date:  2020-02-06       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.